Just quick summary to bring this to your attention; more detail will hopefully follow.

This stock floated yesterday at 10p and has since doubled. It has, needless to say, suddenly become very popular on another BB.

The company is profitable already and trading on an estimated (by yours truly) forward PE for the current year of 9 at SP 20p. EDIT: Hoodless Brennan estimate EPS for Full Year 2006 will be 2.18p - see article (link below).

Free float is 11.4% of the 81.2 million shares in issue - most are held by the directors.







Extremely useful Investegate article LINK


Extremely useful Hoodless Brennan analysis LINK


PDYOR, etc.

cynic never one for you but some are curious when a sleeper goes up 77%.

i was curious too ..... "Curious Yellow" comes to mind!

agree, joke spread, needs to jump about 30% just to profit!!

E U approval confirmed on 24 Sept, this is now going to fly.

DYOR.

sp sudden jump?

Sp up 35%!

I love it, results due by end of month along with the news that we've been waiting for, for ages.

Up 43%, just wait until everyone else finds out. This rise is on the back of current investors stumbling upon EU accreditaion before it being released by the company. Also the market were caught short initially by the surge in buying.

Good luck all, I'm in and staying for the foreseeable future.

News out officially in a rushed RNS timed 11:01, sp still rising.

LOL

Now a 66% gain on the day. Never mind PP, why not trade the rise then.

TIDMTAIH

RNS Number : 7499Z
Taihua Plc
28 September 2009





Taihua plc
("Taihua" or the "Company")


Application Update


Taihua confirms that the European Directorate for the Quality of Medicines has
granted Taihua a certificate of suitability for paclitaxel.
Further information will be provided in due course.


+------------------------------------+------------------------------------+
| Nicholas Lyth, Chairman, Taihua | 0776 990 6686 |
| plc | |
+------------------------------------+------------------------------------+
| Katy Mitchell, WH Ireland Limited | +44 161 832 2174 |
+------------------------------------+------------------------------------+











This information is provided by RNS
The company news service from the London Stock Exchange
END

Sorry now 83%, I cant keep up.

By the way I'm not ramping but merely stating facts as they happen.

Oily, did. Time to offload now.

Cannot get any real volume so its get out quick time now.

up 108% and top of the leader board.

Cheers PP good luck.

Timed that top to perfection :)

All out.

EU approval means nothing, but a nice spike to trade. They are struggling to sell in Asia so have no chance of selling in Europe IMO. Never mind, nice spike :)

Hope people managed to get out, before getting trapped in.

As usual, awful results and a massive move down.

Well done anyone who got the spike and sold at the top, unlucky for anyone still in.

Looks ok now again, just had some dummy tests and there seems to be
very little stock around, sell 150k at a premium buy 2.5k close to full offer.

Swimming against the tide but ready to break out if good news hits about
a european partner will be a big boost, the company is still supported by
a large amount of cash next to their market cap.

Totally expected (if you are sensible and not a ramper)

Anyone thinking different was living on the moon. Remains a large avoid IMO.


RNS Number : 8919G
Taihua Plc
09 February 2010

TAIHUA PLC
("Taihua" or "the Company")

TRADING UPDATE

Taihua plc a China-based pharmaceutical company which manufactures Paclitaxel,
Homoharringtonine and Traditional Chinese Medicines ("TCM") would like to update
its shareholders on its progress in 2009 before the release of its financial
results for the 12 months ended 31 December 2009.

Overview

As disclosed in the AGM Statement of 24 July 2009 and the 2009 interim results
of the Company, the first half of 2009 was very difficult for the business of
Taihua. Impacted by the global financial crisis and foreign exchange rate
fluctuations, the sales volume of Paclitaxel and Homoharringtonine, the
Company's principal products, had decreased when compared to the same period in
2008.

The Company's customers' demands increased in the second half of 2009 compared
to the first half of 2009 (Paclitaxel sales in H1: 4750 grams; Pacliataxel sales
in H2: 6805 grams (an increase of 43.26%) and homoharringtonine sales in H1:
1620 grams and homoharringtonine sales in H2: 3570 grams (an increase of 120%)).
However, the increase was not sufficient to arrest the decline in year end
profits compared with the previous year.

Therefore, although the trading performance of the Company has improved in the
second half of 2009, the sales volume of Paclitaxel and homoharringtonine in
2009, as affected by the poor performance in the first half of 2009, was still
lower than that in 2008.

Paclitaxel and Homoharringtonine

The prices of Paclitaxel and Homoharringtonine remained unchanged in the second
half of 2009.

During 2009, the Company sold 11,555 grams of Paclitaxel, a decrease of 31%
compared to 2008, and 5,190 grams of Homoharringtonine, a decrease of 43%
compared to 2008.

TCM products

The Company has not fully recovered from the adverse influence of the suspension
of TCM production in 2008. As a result, the sales revenue of TCM products in
2009 decreased by 9% compared to 2008.

Outlook

The Company is now concentrating on further discussions with potential European
distributors and expects to conclude the negotiations with potential European
distributors in March 2010.